Switch from biosimilar infliximab CT-P13 to biosimilar infliximab SB-2 in the long-term maintenance therapy in IBD patients – prospective observational study
Original articleGastroent Hepatol 2023; 77(4): 336–341. doi: 10.48095/ccgh2023336
SummaryLiteraturepdf Jindra Reissigová, Karin Černá , Milan Lukáš jr., Milan Lukáš, Veronika Hrubá, Naděžda Machková, Dana Ďuricová, Martin Kolář, Kateřina Vlková, Lea Čermáková